Key facts
- This page summarizes John W. Smither's Form 4 filing for Arcutis Biotherapeutics, Inc. (ARQT).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 15 Feb 2024, 18:23.
John W. Smither - 13 Feb 2024 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- ARQT
- Reported as of
- 13 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Feb 2024, 18:23:45 UTC
- Prior SEC filing
- 03 Jan 2024
- Next SEC filing
- 07 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ John W. Smither
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John W. Smither filed Form 4 for Arcutis Biotherapeutics, Inc. (ARQT) on 15 Feb 2024.
Change
- Previous filing in this sequence was filed on 03 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARQT
transaction
Common Stock
Award
- Transaction value
- Shares
- +2,793
- Change %
- Price
- Shares after
- 2,793
- Date
- 13 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
ARQT
transaction
Common Stock
Award
- Transaction value
- Shares
- +8,572
- Change %
- +307%
- Price
- Shares after
- 11,365
- Date
- 13 Feb 2024
- Ownership
- Direct
- Footnotes
- F2
ARQT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 141,392
- Date
- 13 Feb 2024
- Ownership
- By Trust
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ARQT
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -8,379
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 13 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,379
- Exercise price
- $27.61
- Footnotes
- F1, F4
ARQT
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -25,718
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 13 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,718
- Exercise price
- $32.44
- Footnotes
- F2, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on February 27, 2020, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in four equal quarterly installments commencing May 1, 2024.
Footnote F2
On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2021, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024.
Footnote F3
The securities are held of record by The 1994 Smither Family Trust, as Amended and Restated in 2014, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
Footnote F4
This option is fully vested.
Footnote F5
This option is fully vested.